Bigtec Labs

Bengaluru, India Founded: 2000 • Age: 26 yrs Listed
Point-of-care solutions for nucleic acid amplification tests are developed.
Request Access
Report Incorrect Data
Page last updated

About Bigtec Labs

Bigtec Labs is a publicly listed company based in Bengaluru (India) founded in 2000 by Chandrasekhar Nair and Sriram Natarajan. Point-of-care solutions for nucleic acid amplification tests are developed. Its chief executive, as recorded, is Sriram Natarajan. Its Indian entity Molbio Diagnostics Limited reported revenue of ₹1,459 Cr. Bigtec Labs offers products and services including Truenat and PRORAD. Its focus areas include Life Sciences, Infectious Diseases, In Vitro Diagnostic Tests and Diversified.

Company details

Bigtec Labs was founded in 2000 in Bengaluru, India, and operates in the healthcare diagnostics sector. Portable, battery-operated platforms such as TrueLab Real Time Quantitative micro PCR are provided for molecular detection of infectious diseases. Nucleic acid amplification tests are enabled through these point-of-care solutions, supporting on-site diagnostics in resource-limited settings. Operations focus on quantitative real-time PCR technology for clinical applications.

  • Headquarters Bengaluru, India
  • Founders Chandrasekhar Nair, Sriram Natarajan
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website bigteclabs.com
  • Social LinkedIn YouTube
  • Legal Name Molbio Diagnostics Limited
  • Date of Incorporation 20 Oct, 2000
  • Jurisdiction Salcete, Goa, India
Operational Areas
Healthcare → Life Sciences Platforms & Tools
Healthcare → Clinical Genomics
Healthcare → Infectious Diseases
Key Metrics
  • Market Cap
    ₹15,675 Cr

    MOLBIO · NSE

  • Share Price
    ₹1,336.00

    -1.78% today

  • Revenue
    ₹1,446 Cr

    FY 2025-26 · +41.7% YoY

  • EBITDA
    ₹315 Cr

    Margin 21.8%

  • Net Profit
    ₹167 Cr

    FY 2025-26 · +10.0% YoY

  • P/E (TTM)
    92.3x

    P/B 11.3x

  • ROE
    15.4%

    ROCE 19.1%

  • Debt / Equity
    0.28

    Interest cover 13.3x

Products & Services of Bigtec Labs

Bigtec Labs offers a comprehensive portfolio of products and services, including Truenat and PRORAD.

Truenat
Diagnostic Device

Rapid molecular testing for infectious diseases like TB.

PRORAD
Medical Imaging

Portable X-ray machine for out-of-clinic screening.

Apps and channels of Bigtec Labs

its YouTube channel Bigtec Labs has 34 subscribers and 1 videos.

Bigtec Labs
YouTube 34 subscribers 1 videos Autos & Vehicles
Open channel

Videos from Bigtec Labs

The most watched videos on Bigtec Labs's YouTube channel, Bigtec Labs (34 subscribers). Click a video to play it here.

The Bigtec Way
680 views

More on Bigtec Labs .

Board of directors of Molbio Diagnostics Limited (Bigtec Labs)

Molbio Diagnostics Limited is the primary company behind Bigtec Labs. The boards of the 2 registered companies of Bigtec Labs currently have 6 directors; the longest-serving is Chandrasekhar Bhaskaran Nair, appointed in 2011. 25 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Chandrasekhar Bhaskaran Nair
DIN 01787875
Director01 Aug 201115 yrs 3 moMolbio Diagnostics Limited, Bigtec Private Limited
Sangeetha Sriram
DIN 02103165
Director19 Jun 20206 yrs 4 moMolbio Diagnostics Limited, Bigtec Private Limited
Sriram Natarajan
DIN 00013843
CEO10 Jul 20233 yrs 4 moMolbio Diagnostics Limited, Bigtec Private Limited
Arunkumar Jha
DIN 01235238
Director16 Nov 20241 yr 11 moMolbio Diagnostics Limited
Balram Bhargava
DIN 10479707
Director16 Nov 20241 yr 11 moMolbio Diagnostics Limited
Nupur Garg
DIN 03414074
Director31 Jan 20251 yr 9 moMolbio Diagnostics Limited

People of Bigtec Labs

10 people are tracked at Bigtec Labs (5 in leadership, 5 in team).

NameRoleGroup
Chandrasekhar Nair
Co-Founder & CTOLeadership
Sriram Natarajan
Co-Founder & CEOLeadership
Abhishek Haldar
Head Of Human ResourcesLeadership
Naresh Baliga
General Manager MicrofabLeadership
Anita Chandrasekhar
Head Of OperationsLeadership
Megha Nayak
Executive Finance & AccountsTeam
Niranjan Jha
Senior Manager - Strategy & PartnershipsTeam
Karthik P
Executive - AdminTeam
Prakash B
Senior Research AssociateTeam
Swaminathan Raghavan
Deputy ManagerTeam
Premium access

Complete people profiles for Bigtec Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Bigtec Labs

Bigtec Labs is a publicly listed company on the NSE with ticker symbol MOLBIO in India. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • Listed onNSE: MOLBIO
  • Listed entityMolbio Diagnostics Limited

Financials of Bigtec Labs

Exchange-reported figures of Molbio Diagnostics Limited, the listed company behind Bigtec Labs (NSE: MOLBIO).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,446 Cr
+41.7% YoY
EBITDA
₹315 Cr
+27.0% YoY
Profit After Tax
₹167 Cr
+10.0% YoY
Net Worth
₹1,169 Cr
+20.7% YoY
Total Assets
₹1,768 Cr
+54.7% YoY
Total Debt
₹450 Cr
+206.3% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24
Income statement
Revenue1,4461,020837
Revenue growth+41.7%+22.0%-
EBITDA315248181
EBITDA margin+21.8%+24.3%+21.6%
Profit before tax231194130
Net profit167152128
Net profit margin+11.6%+14.9%+15.3%
EPS (₹)14.7764.32452.32
Balance sheet
Total assets1,7681,1431,039
Net worth1,169968823
Total debt450147184
Cash & bank36712922.11
Net working capital1,038612644
Cash flow
Cash from operations50.392879.57
Cash from investing(53.91)(123)(45.01)
Cash from financing276(26.15)(31.55)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue25940856120558099.71
Revenue growth (YoY)-55.4%+309.6%----
Other income5.773.104.792.841.090.76
EBITDA43.951011598.70167(16.10)
EBITDA margin+17.0%+24.6%+28.3%+4.2%+28.9%-16.1%
Depreciation23.3617.0819.6017.9113.8112.32
Interest8.8610.7012.0810.806.983.61
Profit before tax17.5075.91132(17.17)148(31.27)
Tax9.8023.1736.01(2.57)40.89(7.33)
Net profit7.7052.7495.82(14.60)107(23.94)
EPS (₹)1.335.218.050.009.74(2.10)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,3139717563277761,271
Revenue growth+35.2%+28.4%+131.6%-57.9%-38.9%-
EBITDA24921717740.08319595
EBITDA margin+18.9%+22.3%+23.4%+12.3%+41.1%+46.8%
Profit before tax19818815222.85258549
Net profit14714612815.54187410
Net profit margin+11.2%+15.0%+16.9%+4.8%+24.1%+32.2%
EPS (₹)12.8361.98492.9368.97833.472,026.76
Balance sheet
Total assets1,4861,018921796791594
Net worth1,135990850739683335
Total debt34626.2070.2457.18105257
Cash & bank10911118.264.586.3915.87
Net working capital749537567488549377
Cash flow
Cash from operations(37.98)24937.7467.9097.78344
Cash from investing(256)(97.90)(31.44)(51.01)(86.72)(142)
Cash from financing292(17.35)(24.20)30.96(20.01)(192)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue24939943920057995.32
Revenue growth (YoY)-57.0%+319.0%----
Other income3.971.372.741.901.591.48
Total expenses190308332183445105
EBITDA58.6491.6410717.09134(9.64)
EBITDA margin+23.6%+22.9%+24.4%+8.5%+23.2%-10.1%
Depreciation13.998.429.859.738.757.41
Interest6.278.669.288.083.911.89
Profit before tax42.3575.9390.651.18123(17.46)
Tax10.9719.3024.970.1131.21(4.06)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue25940856120558099.71
Revenue growth (YoY)-55.4%+309.6%----
Other income5.773.104.792.841.090.76
EBITDA43.951011598.70167(16.10)
EBITDA margin+17.0%+24.6%+28.3%+4.2%+28.9%-16.1%
Depreciation23.3617.0819.6017.9113.8112.32
Interest8.8610.7012.0810.806.983.61
Profit before tax17.5075.91132(17.17)148(31.27)
Tax9.8023.1736.01(2.57)40.89(7.33)
Net profit7.7052.7495.82(14.60)107(23.94)
EPS (₹)1.335.218.050.009.74(2.10)
ParticularsFY 2025-26FY 2024-25FY 2023-24
Revenue1,4461,020837
Revenue growth+41.7%+22.0%-
Other income13.338.704.10
Total expenses1,131772656
Employee cost14510363.89
EBITDA315248181
EBITDA margin+21.8%+24.3%+21.6%
Depreciation63.6444.5541.01
Interest33.4717.6614.45
Profit before tax231194130
Tax66.9955.8546.09
Net profit167152128
Net profit margin+11.6%+14.9%+15.3%
EPS (₹)14.7764.32452.32
ParticularsFY 2025-26FY 2024-25FY 2023-24
Equity & liabilities
Share capital11.282.262.25
Reserves & surplus1,158966821
Shareholders' funds (net worth)1,169968823
Minority interest139(1.11)5.46
Secured loans33617.4166.40
Unsecured loans114130117
Total debt450147184
Total liabilities1,7681,1431,039
Assets
Gross block787485448
Net block536290289
Capital work in progress11.3227.331.58
Investments5.9845.575.99
Inventories449436315
Sundry debtors409272425
Cash & bank balances36712922.11
Loans & advances16093.2160.46
Total current assets1,385930823
Total current liabilities347318179
Net working capital1,038612644
Total assets1,7681,1431,039
ParticularsFY 2025-26FY 2024-25FY 2023-24
Opening cash63.23(75.07)(8.08)
Net cash from operating activities50.392879.57
Net cash from investing activities(53.91)(123)(45.01)
Net cash from financing activities276(26.15)(31.55)
Net change in cash273138(66.99)
Closing cash36712922.11
ParticularsFY 2025-26FY 2024-25FY 2023-24
Growth
Sales growth+41.7%+22.0%-
EBITDA growth+27.0%+37.0%-
PBT growth+18.9%+50.0%+9997.0%
Net income growth+10.0%+18.4%-
Profitability & leverage
Net income margin+11.4%+13.6%+10.0%
Return on capital employed+19.1%+19.5%+20.7%
Return on net worth+15.4%+15.5%+14.2%
Debt / equity0.280.180.20
Long-term debt / equity0.120.020.05
Interest cover13.328.6810.32
Efficiency & per share
Fixed asset turnover2.272.192.00
Inventory turnover3.272.722.53
Debtors turnover4.252.932.72
EPS (₹)14.7764.32452.32
Dividend per share (₹)0.000.000.00
Book value per share (₹)103.70429.253,651.42
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue24939943920057995.32
Revenue growth (YoY)-57.0%+319.0%----
Other income3.971.372.741.901.591.48
Total expenses190308332183445105
EBITDA58.6491.6410717.09134(9.64)
EBITDA margin+23.6%+22.9%+24.4%+8.5%+23.2%-10.1%
Depreciation13.998.429.859.738.757.41
Interest6.278.669.288.083.911.89
Profit before tax42.3575.9390.651.18123(17.46)
Tax10.9719.3024.970.1131.21(4.06)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,3139717563277761,271
Revenue growth+35.2%+28.4%+131.6%-57.9%-38.9%-
Other income7.726.376.528.105.111.48
Total expenses1,065754580286457676
Employee cost0.0065.6538.6034.0128.8177.81
EBITDA24921717740.08319595
EBITDA margin+18.9%+22.3%+23.4%+12.3%+41.1%+46.8%
Depreciation35.7326.3123.6019.3941.7512.03
Interest23.158.867.615.9424.8635.24
Profit before tax19818815222.85258549
Tax52.9248.2240.797.3170.57139
Net profit14714612815.54187410
Net profit margin+11.2%+15.0%+16.9%+4.8%+24.1%+32.2%
EPS (₹)12.8361.98492.9368.97833.472,026.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.282.262.252.252.252.02
Reserves & surplus1,123988847736681333
Shareholders' funds (net worth)1,135990850739683335
Secured loans33517.4125.5837.981.31157
Unsecured loans11.388.7944.6619.2010499.33
Total debt34626.2070.2457.18105257
Total liabilities1,4861,018921796791594
Assets
Gross block40733330026023466.17
Net block25721520918918254.81
Capital work in progress5.6217.601.580.000.00100
Investments31795.3553.7953.798.748.74
Inventories397410293328296265
Sundry debtors359228360173241211
Cash & bank balances10911118.264.586.3915.87
Loans & advances13977.7952.3810588.9096.91
Total current assets1,004827724611632589
Total current liabilities25429015712382.79213
Net working capital749537567488549377
Total assets1,4861,018921796791594
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash111(22.56)(4.65)(52.49)14.955.37
Net cash from operating activities(37.98)24937.7467.9097.78344
Net cash from investing activities(256)(97.90)(31.44)(51.01)(86.72)(142)
Net cash from financing activities292(17.35)(24.20)30.96(20.01)(192)
Net change in cash(1.84)133(17.91)47.84(8.94)9.58
Closing cash10911118.264.586.3915.87
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+35.2%+28.4%+131.6%-57.9%-38.9%-
EBITDA growth+14.7%+22.8%+340.6%-87.5%-46.3%-
PBT growth+5.1%+23.8%+564.7%-91.1%-53.1%+9997.0%
Net income growth+0.9%+13.7%+723.9%-91.7%-54.3%-
Revenue CAGR (3Y)+59.0%+7.8%-15.9%---
EBITDA CAGR (3Y)+83.8%-12.1%-33.3%---
Profitability & leverage
Net income margin+11.0%+14.4%+14.7%+4.8%+24.1%+32.2%
Return on capital employed+17.6%+20.3%+21.8%+3.6%+40.8%+127.4%
Return on net worth+13.6%+15.2%+16.1%+2.2%+36.8%+310.6%
Debt / equity0.180.050.080.110.362.47
Long-term debt / equity0.110.020.010.000.161.48
Interest cover10.874.654.9728.718.966.05
Efficiency & per share
Fixed asset turnover3.553.072.701.325.1721.09
Inventory turnover3.252.762.441.052.777.88
Debtors turnover4.483.302.831.583.4310.92
EPS (₹)12.8361.98492.9368.97833.472,026.76
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)100.63438.863,769.453,276.953,042.221,655.09

Web traffic of Bigtec Labs

The website of Bigtec Labs (bigteclabs.com) receives about 1.1K visits a month.

  • Monthly visits
    1.1K

    ▼ 3.6% vs previous month

Similar websites

Websites whose visitors overlap most with Bigtec Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
Camson Bio Technologies
camsonbiotechnologies.com
40%
View details
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Bigtec Labs

Motilal Oswal initiates coverage on Molbio Diagnostics stock with Buy, sees 21% upside. Here's why - The Economic Times
Economic Times • 1 month ago
Buy Molbio Diagnostics; target of Rs 1800: Motilal Oswal
Moneycontrol • 1 month ago
Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal | Newly listed stock up 71% from IPO price | Stock Market News
mint • 1 month ago
Motilal Oswal Alternates sells over 2% stake in Molbio Diagnostics for ₹306 cr - The HinduBusinessLine
Thehindubusinessline • 1 month ago
Molbio Diagnostics shares rally 9% as Jefferies initiates 'high conviction top pick' call for recently listed stock. Why is it bullish? - The Economic Times
Economic Times • 1 month ago
Recently listed Molbio Diagnostics share price falls 9%: Healthcare stock loses 18.5% in 2 days after blockbuster rally | Stock Market News
mint • 1 month ago
Molbio Diagnostics shares rally 30% in 2 days, jump 80% since debut. What lies ahead? - The Economic Times
Economic Times • 2 months ago
Saraswati Saree Depot Ltd leads gainers in 'B' group | Capital Market News - Business Standard
Business Standard • 2 months ago
Molbio Diagnostics hits 20% upper circuit on heavy volume; up 35% in 2 days | Markets News - Business Standard
Business Standard • 2 months ago
Molbio Diagnostics reports Q2 profit; Jayaswal Neco clarifies relationship; Morepen Labs expands capacity
Moneycontrol • 2 months ago
Premium access

Complete news archive for Bigtec Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Bigtec Labs

Bigtec Labs was founded in 2000.

Bigtec Labs is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.

Sriram Natarajan is the CEO of Bigtec Labs, as recorded in our data. They have also founded this company.

The primary company behind Bigtec Labs, Molbio Diagnostics Limited, reported revenue of ₹1,459 Cr for FY 2026, up 42% year on year.

Bigtec Labs was founded in 2000 in Bengaluru, India, and operates in the healthcare diagnostics sector. Portable, battery-operated platforms such as TrueLab Real Time Quantitative micro PCR are provided for molecular detection of infectious diseases. Nucleic acid amplification tests are enabled through these point-of-care solutions, supporting on-site diagnostics in resource-limited settings. Operations focus on quantitative real-time PCR technology for clinical applications.

Bigtec Labs offers Truenat and PRORAD.

Yes, Bigtec Labs is publicly traded on NSE under the ticker symbol MOLBIO.

Bigtec Labs is associated with 2 legal entities: Molbio Diagnostics Limited, Bigtec Private Limited.

The legal entities of Bigtec Labs currently have 7 directors, including Arunkumar Jha, Chandrasekhar Bhaskaran Nair, Balram Bhargava and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available